

**Reference:** FOI 33841 BUCKS 14Y

**Subject:** Urology Products

*I can confirm that the CCG does not hold some of the information requested; please see responses below:*

QUESTION	RESPONSE
<p><i>For the purposes of the FOIA request, we are only interested in catheters for self-intermittent catheterisation. We are not interested in indwelling catheters, sheaths, leg bags, night bags, catheter valves, retaining straps, bag sleeves, drainable dribbling devices, belts, urinal systems or absorbent pads.</i></p>	
<p><b>1. Does your organisation have a formulary for urology products, and, if so, please can you provide a link to it?</b></p>	<p>The CCG has Bucks Continence Appliance Prescribing Guidelines which are due for review – see link below  <a href="http://www.bucksformulary.nhs.uk/docs/Guideline_823FM.pdf?UID=6441740962019123125518">http://www.bucksformulary.nhs.uk/docs/Guideline_823FM.pdf?UID=6441740962019123125518</a></p>
<p><b>2. Does your formulary contain a statement making it clear that notwithstanding the contents of that formulary it is a clinician's right, and indeed their duty, to prescribe whichever product on Part IX of the Drug Tariff they consider best meets the needs of their patient?</b></p>	<p>Yes ref page 3 of guideline</p>
<p><b>3. Does your formulary contain a clear and functioning link to Part IX of the Drug Tariff?</b></p>	<p>Yes on page 4 of guideline a link to drug tariff is provided</p>

<p><b>4. If your formulary does not contain a statement as in 2. above, or a link as in 3. above, do you intend to update it to include that information?</b></p>	<p>Not applicable</p>
<p><b>5. Please supply the name, position and email address of whoever in your organisation is responsible for any formulary that has been developed or which may be developed in future.</b></p>	<p>Details of original author and contributors can be found on page 3 of the document. Going forward it is likely to be a joint team of healthcare professionals to produce any further revisions of the document. The author will longer be working for the CCG after Dec 31<sup>st</sup> 2019</p>
<p><b>6. Is it your intention that if a new formulary is to be developed or an existing one is to be reviewed you will:</b></p> <p><b>a. Include a clear reference to the Drug Tariff as in point 2. above; and</b></p> <p><b>b. Notify the Urology Trade Association at <a href="mailto:uta@whitehouseconsulting.co.uk">uta@whitehouseconsulting.co.uk</a> that such a project is being taken forward so that our members can be informed.</b></p>	<p>Reference to drug tariff already included.</p>
<p><b>7. What steps do you take to ensure that clinicians and nurses are familiar with and trained in the assessment and appropriate use of urology products on Part IX on the Drug Tariff?</b></p>	<p>The CCG does not hold this information. Please contact our provider, Buckinghamshire Hospitals NHS Trust who may hold this information. I have provided a link for your convenience:</p> <p style="text-align: center;"><a href="#">Buckinghamshire Healthcare NHS Trust</a></p>

*The information provided in this response is accurate as of 05 December 2019, and has been authorised for release by Robert Majilton, Deputy Chief Officer and Director of Sustainability & Transformation for NHS Buckinghamshire CCG.*